Chemomab Therapeutics Ltd. Sponsored ADR CMMB

2.16 (0.04) (1.82%) as of 25 Sep
Market cap
$16.0M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '19 Jan '20 Dec '20 Jan '21 Dec '21 Jan '22 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
4.42 2.37 9.00 23.66 23.66 6.18 6.18 4.32 4.98 9.08
Net Debt/EBITDA
0.78 0.50 1.97 4.96 4.96 1.41 1.40 0.78 0.98 1.09
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
0.61 1.10 0.88 0.99 0.99 0.74 0.74 0.97 1.10 1.24
Capex/Depreciation
(0.34) 0.00 (1.58) 0.00 22.38 0.00 (1.17) (0.04) 0.00 (0.04)
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
(181.93%) (125.60%) (82.77%) (34.56%) (20.30%) (56.38%) (76.32%) (91.02%) (91.34%) (69.54%)
ROA
(137.30%) (89.53%) (63.80%) (32.50%) (19.39%) (51.27%) (64.20%) (74.28%) (71.30%) (58.45%)
ROIC
0.00% 0.00% 0.00% 0.00% (2,534.22%) 0.00% 0.00% 0.00% 0.00% (303.83%)
Return on Tangible Assets
(190.37%) (327.75%) (55.75%) (20.56%) (20.66%) (77.39%) (78.20%) (148.03%) (106.68%) (74.20%)
Average Days of Receivables
0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% — 0.00% — 0.00% — 0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(153.84) (6.85) (3.09) (1.19) (4.48) (1.78) (7.18) (8.04) (3.43) (1.75)
Cash per Share
163.34 2.91 6.84 5.90 23.58 3.51 14.05 6.76 3.20 1.63
Shareholders Equity per Share
138.56 1.93 6.32 5.93 23.70 3.18 12.73 5.79 3.02 1.93
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
138.56 1.93 6.32 5.93 23.70 3.18 12.73 5.79 3.02 1.93
Free Cash Flow
(16.55) (12.71) (5.28) (12.38) (11.61) (20.29) (20.44) (23.61) (15.39) (11.13)
Working Capital
14.09 3.53 10.52 60.04 60.04 34.99 34.99 16.06 12.82 11.95
Capital Expenditures
(0.09) (0.03) (0.04) (0.24) 0.76 (0.07) (0.07) 0.00 — 0.00
Net Current Asset Value
13.37 3.51 10.17 59.80 59.80 34.90 34.90 15.74 12.61 11.95
Other line items
Quick Ratio
4.36 2.09 9.00 23.15 23.66 5.99 6.18 4.32 4.98 9.08
Depreciation/Fixed assets
1.78 6.67 0.16 0.05 0.10 0.10 0.16 0.22 0.21 0.40
Cash ROIC
(51.15%) (141.87%) (23.97%) (10.67%) (10.38%) (27.41%) (27.22%) (64.88%) (56.09%) (49.81%)
Accounts Receivable Turnover
0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— 0.00 — 0.00 — 0.00 — — — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— 0.00 — 0.00 — 0.00 — — — —
Revenue per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
(152.96) (6.85) (3.07) (1.19) (4.77) (1.78) (7.16) (8.04) (3.43) (1.75)
Capex per Share
(0.88) 0.00 (0.02) 0.00 0.29 0.00 (0.02) 0.00 0.00 0.00
Average Receivables
0.52 — 0.27 0.16 0.85 0.99 1.11 1.40 1.37 2.38
Average Payables
0.88 0.78 0.39 0.71 1.34 1.51 1.69 1.10 0.57 0.56
Average Assets
19.76 12.97 9.33 38.41 64.35 53.71 43.06 32.61 19.56 15.39
Average Common Equity
14.91 9.24 7.19 36.13 61.47 48.84 36.22 26.61 15.27 12.94
Capex to Sales
0.00 — 0.00 — 0.00 — 0.00 0.00 — 0.00
Net Profit Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Fold the line items

Columns are period end dates